PrescriptionDrugs.org

What to Expect When Starting Aripiprazole

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Aripiprazole (Abilify) is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, major depressive disorder (as an add-on), autism-related irritability, and Tourette syndrome. It works differently from older antipsychotics by partially activating dopamine receptors rather than fully blocking them. Full therapeutic effects typically require 2-6 weeks, though some symptom improvement may begin earlier.

Week-by-week timeline

Week 1

Starting Treatment

Common early side effects include restlessness (akathisia), insomnia, nausea, headache, and light-headedness. Akathisia — a feeling of inner restlessness or need to move — affects some patients and should be reported to your prescriber. Start at the prescribed dose, which is often lower than the target dose.

Week 2-3

Adjustment Period

Side effects often improve as your body adjusts. Akathisia, if present, may be treated with a dose reduction or added medication. Some patients notice improved sleep and reduced agitation before full antipsychotic effects emerge.

Week 3-6

Early Therapeutic Effects

Psychotic symptoms (hallucinations, delusions) in schizophrenia typically begin to improve by weeks 3-6. For bipolar mania, stabilization may occur sooner. For depression augmentation, improvement is often seen at 2-4 weeks.

Month 1-2

Dose Optimization

Your prescriber may adjust the dose based on response and tolerability. Aripiprazole doses range from 2-30 mg depending on the indication. Weight and metabolic parameters should be checked — aripiprazole has lower metabolic risk than many antipsychotics but can still cause weight gain.

Month 2-3

Stabilization

Most patients achieve stable symptom control by 2-3 months. Long-term monitoring includes metabolic labs, movement assessments (for tardive dyskinesia), and blood pressure. Do not stop abruptly without consulting your doctor.

When to call your doctor

Contact your healthcare provider if you experience:

  • Severe restlessness or inability to sit still that is distressing (akathisia)
  • Uncontrolled muscle movements: grimacing, lip smacking, repetitive movements (possible tardive dyskinesia)
  • High fever, muscle rigidity, confusion, irregular heartbeat (neuroleptic malignant syndrome — medical emergency)
  • Worsening depression or thoughts of self-harm
  • Compulsive behaviors you cannot control: gambling, eating, shopping, sexual urges (a known side effect of aripiprazole)
  • Fainting or irregular heartbeat
  • Difficulty swallowing

Tips for getting started

Take aripiprazole at the same time each day. It can be taken with or without food. If akathisia (restlessness) is bothersome, do not suffer silently — tell your prescriber, as dose adjustments or additional medications can help. Monitor your weight and report significant gain. Avoid alcohol. Do not stop suddenly — psychiatric symptoms can return and withdrawal effects can occur. If you are switching from another antipsychotic, your prescriber will manage the cross-taper.

Frequently asked questions

More about Aripiprazole

References

  1. [Regulatory] FDA Label: Abilify (aripiprazole) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021436s038021713s030021729s022lbl.pdf Accessed 2026-03-01.
  2. [Regulatory] NIH MedlinePlus: Aripiprazole https://medlineplus.gov/druginfo/meds/a603012.html Accessed 2026-03-01.
  3. [Regulatory] FDA Drug Safety: Impulse-Control Problems with Aripiprazole https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-new-impulse-control-problems-associated-mental-health-drug-aripiprazole-abilify Accessed 2026-03-01.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: